Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05722418 · ClinicalTrials.gov registry record · Phase 1
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Caribou Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 16
- Study locations
NCT05722418 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by Caribou Biosciences. The registered enrollment target is 50 participants, below the 175-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (71% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT05722418, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Caribou Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Conditions Studied
Interventions
- BIOLOGICAL CB-011
Study Locations (16)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
- Duke University Health System (DUHS) - Durham
Ohio
- Oncology Hematology Care, Inc - Cincinnati
- Cleveland Clinic - Cleveland
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion - Aurora
Florida
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics - Miami
Kentucky
- University of Kentucky/ Markey Cancer Center - Lexington
New Jersey
- Hackensack Meridian John Theurer Cancer Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05722418
The ClinicalTrials.gov registry entry for NCT05722418 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (71% lower). The listed sponsor is Caribou Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CB-011 is the first listed.
NCT05722418 reports 16 study locations spanning 13 distinct geographic areas - top geographies include New York, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05722418 about?
NCT05722418 is a clinical study titled "CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma". This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma...
What is the current status of trial NCT05722418?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-02-06. Estimated completion is 2027-12.
What conditions does trial NCT05722418 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT05722418?
The interventions under investigation include: CB-011 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05722418?
This trial is sponsored by Caribou Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05722418 being conducted?
This trial has 16 study locations across Alabama, Colorado, Florida, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.